The Occlusive Arterial Disease (OAD) drugs in development market research report provides comprehensive information on the therapeutics under development for Occlusive Arterial Disease (OAD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Occlusive Arterial Disease (OAD). Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Occlusive Arterial Disease (OAD) and features dormant and discontinued products.

GlobalData tracks 54 drugs in development for Occlusive Arterial Disease (OAD) by 48 companies/universities/institutes. The top development phase for Occlusive Arterial Disease (OAD) is preclinical with 23 drugs in that stage. The Occlusive Arterial Disease (OAD) pipeline has 53 drugs in development by companies and one by universities/ institutes. Some of the companies in the Occlusive Arterial Disease (OAD) pipeline products market are: Beijing Tide Pharmaceutical, MediaPharma and VESSL Therapeutics.

The key targets in the Occlusive Arterial Disease (OAD) pipeline products market include Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF), Prostaglandin E2 Receptor EP1 Subtype (Prostanoid EP1 Receptor or PTGER1), and Vascular Endothelial Growth Factor A (Vascular Permeability Factor or VEGFA).

The key mechanisms of action in the Occlusive Arterial Disease (OAD) pipeline product include Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Activator with four drugs in Pre-Registration. The Occlusive Arterial Disease (OAD) pipeline products include 13 routes of administration with the top ROA being Intravenous and 12 key molecule types in the Occlusive Arterial Disease (OAD) pipeline products market including Small Molecule, and Cell Therapy.

Occlusive Arterial Disease (OAD) overview

Occlusive arterial disease (OAD), also known as peripheral arterial disease (PAD) or peripheral vascular disease (PVD), is characterized by the narrowing or blockage of arteries in the extremities, particularly the legs. This occurs due to atherosclerosis, a buildup of plaque made up of cholesterol, fats, calcium, and other substances within the arterial walls. Individuals with OAD may experience symptoms such as leg pain, cramping, or numbness during physical activity (claudication). The pain typically improves with rest but returns upon resuming activity. In severe cases, reduced blood flow can cause tissue damage, leading to non-healing ulcers or even gangrene. Factors contributing to the development of OAD include smoking, diabetes, high blood pressure, high cholesterol, obesity, ssedentary lifestyle, advanced age, and family history of cardiovascular disease.

For a complete picture of Occlusive Arterial Disease (OAD)’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.